Empagliflozin in patients hospitalized for acute decompensated heart failure: an expert resolution on the discussion of the EMPULSE trial
An online expert meeting held on November 17, 2021 reviewed the results of the randomized, double-blind, multinational, parallel-group EMPULSE trial, evaluating the clinical benefit and safety of the sodium-glucose co-transporter-2 inhibitor (SGLT2i) empagliflozin compared with placebo in patients h...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2022-04-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/4945 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849689784012767232 |
|---|---|
| author | Yu. M. Lopatin G. P. Arutyunov A. S. Ametov F. T. Ageev M. B. Antsiferov O. L. Barbarash S. V. Villevalde N. G. Vinogradova G. R. Galstyan A. S. Galyavich S. R. Gilyarevsky M. G. Glezer I. V. Zhirov M. V. Ilyin A. Yu. Lebedeva S. V. Nedogoda V. V. Salukhov E. I. Tarlovskaya S. N. Tereshchenko I. V. Fomin Yu. Sh. Khalimov D. V. Cherkashin |
| author_facet | Yu. M. Lopatin G. P. Arutyunov A. S. Ametov F. T. Ageev M. B. Antsiferov O. L. Barbarash S. V. Villevalde N. G. Vinogradova G. R. Galstyan A. S. Galyavich S. R. Gilyarevsky M. G. Glezer I. V. Zhirov M. V. Ilyin A. Yu. Lebedeva S. V. Nedogoda V. V. Salukhov E. I. Tarlovskaya S. N. Tereshchenko I. V. Fomin Yu. Sh. Khalimov D. V. Cherkashin |
| author_sort | Yu. M. Lopatin |
| collection | DOAJ |
| description | An online expert meeting held on November 17, 2021 reviewed the results of the randomized, double-blind, multinational, parallel-group EMPULSE trial, evaluating the clinical benefit and safety of the sodium-glucose co-transporter-2 inhibitor (SGLT2i) empagliflozin compared with placebo in patients hospitalized with acute decompensated heart failure (ADHF). Patients were included in the study regardless of ejection fraction (EF) and the presence of diabetes and randomized during hospitalization after stabilization. In addition, the EMPULSE trial used a composite result analyzed using a stratified benefit ratio — Win Ratio analysis. There is evidence of clinical benefit of empagliflozin in hospitalized patients with preserved and reduced LVEF, as well as in patients with newly diagnosed ADHF or with acute decompensation of chronic heart failure (CHF) compared with placebo, regardless of type 2 diabetes presence. The importance of the favorable results of the EMPULSE trial and its significance for clinical practice, which implies the early administration of empagliflozin for inpatients, is noted. A number of proposals have been adopted to accelerate the introduction of empagliflozin into clinical practice for patients with ADHF. |
| format | Article |
| id | doaj-art-ee648580dd8b4bcaa3917713fdc86a35 |
| institution | DOAJ |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| publishDate | 2022-04-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj-art-ee648580dd8b4bcaa3917713fdc86a352025-08-20T03:21:31Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202022-04-0127310.15829/1560-4071-2022-49453523Empagliflozin in patients hospitalized for acute decompensated heart failure: an expert resolution on the discussion of the EMPULSE trialYu. M. LopatinG. P. ArutyunovA. S. AmetovF. T. AgeevM. B. AntsiferovO. L. BarbarashS. V. VillevaldeN. G. VinogradovaG. R. GalstyanA. S. GalyavichS. R. GilyarevskyM. G. GlezerI. V. ZhirovM. V. IlyinA. Yu. LebedevaS. V. NedogodaV. V. SalukhovE. I. TarlovskayaS. N. TereshchenkoI. V. FominYu. Sh. KhalimovD. V. CherkashinAn online expert meeting held on November 17, 2021 reviewed the results of the randomized, double-blind, multinational, parallel-group EMPULSE trial, evaluating the clinical benefit and safety of the sodium-glucose co-transporter-2 inhibitor (SGLT2i) empagliflozin compared with placebo in patients hospitalized with acute decompensated heart failure (ADHF). Patients were included in the study regardless of ejection fraction (EF) and the presence of diabetes and randomized during hospitalization after stabilization. In addition, the EMPULSE trial used a composite result analyzed using a stratified benefit ratio — Win Ratio analysis. There is evidence of clinical benefit of empagliflozin in hospitalized patients with preserved and reduced LVEF, as well as in patients with newly diagnosed ADHF or with acute decompensation of chronic heart failure (CHF) compared with placebo, regardless of type 2 diabetes presence. The importance of the favorable results of the EMPULSE trial and its significance for clinical practice, which implies the early administration of empagliflozin for inpatients, is noted. A number of proposals have been adopted to accelerate the introduction of empagliflozin into clinical practice for patients with ADHF.https://russjcardiol.elpub.ru/jour/article/view/4945empagliflozinheart failurehospitalizationacute decompensated heart failureempulse trialwin ratio analysis |
| spellingShingle | Yu. M. Lopatin G. P. Arutyunov A. S. Ametov F. T. Ageev M. B. Antsiferov O. L. Barbarash S. V. Villevalde N. G. Vinogradova G. R. Galstyan A. S. Galyavich S. R. Gilyarevsky M. G. Glezer I. V. Zhirov M. V. Ilyin A. Yu. Lebedeva S. V. Nedogoda V. V. Salukhov E. I. Tarlovskaya S. N. Tereshchenko I. V. Fomin Yu. Sh. Khalimov D. V. Cherkashin Empagliflozin in patients hospitalized for acute decompensated heart failure: an expert resolution on the discussion of the EMPULSE trial Российский кардиологический журнал empagliflozin heart failure hospitalization acute decompensated heart failure empulse trial win ratio analysis |
| title | Empagliflozin in patients hospitalized for acute decompensated heart failure: an expert resolution on the discussion of the EMPULSE trial |
| title_full | Empagliflozin in patients hospitalized for acute decompensated heart failure: an expert resolution on the discussion of the EMPULSE trial |
| title_fullStr | Empagliflozin in patients hospitalized for acute decompensated heart failure: an expert resolution on the discussion of the EMPULSE trial |
| title_full_unstemmed | Empagliflozin in patients hospitalized for acute decompensated heart failure: an expert resolution on the discussion of the EMPULSE trial |
| title_short | Empagliflozin in patients hospitalized for acute decompensated heart failure: an expert resolution on the discussion of the EMPULSE trial |
| title_sort | empagliflozin in patients hospitalized for acute decompensated heart failure an expert resolution on the discussion of the empulse trial |
| topic | empagliflozin heart failure hospitalization acute decompensated heart failure empulse trial win ratio analysis |
| url | https://russjcardiol.elpub.ru/jour/article/view/4945 |
| work_keys_str_mv | AT yumlopatin empagliflozininpatientshospitalizedforacutedecompensatedheartfailureanexpertresolutiononthediscussionoftheempulsetrial AT gparutyunov empagliflozininpatientshospitalizedforacutedecompensatedheartfailureanexpertresolutiononthediscussionoftheempulsetrial AT asametov empagliflozininpatientshospitalizedforacutedecompensatedheartfailureanexpertresolutiononthediscussionoftheempulsetrial AT ftageev empagliflozininpatientshospitalizedforacutedecompensatedheartfailureanexpertresolutiononthediscussionoftheempulsetrial AT mbantsiferov empagliflozininpatientshospitalizedforacutedecompensatedheartfailureanexpertresolutiononthediscussionoftheempulsetrial AT olbarbarash empagliflozininpatientshospitalizedforacutedecompensatedheartfailureanexpertresolutiononthediscussionoftheempulsetrial AT svvillevalde empagliflozininpatientshospitalizedforacutedecompensatedheartfailureanexpertresolutiononthediscussionoftheempulsetrial AT ngvinogradova empagliflozininpatientshospitalizedforacutedecompensatedheartfailureanexpertresolutiononthediscussionoftheempulsetrial AT grgalstyan empagliflozininpatientshospitalizedforacutedecompensatedheartfailureanexpertresolutiononthediscussionoftheempulsetrial AT asgalyavich empagliflozininpatientshospitalizedforacutedecompensatedheartfailureanexpertresolutiononthediscussionoftheempulsetrial AT srgilyarevsky empagliflozininpatientshospitalizedforacutedecompensatedheartfailureanexpertresolutiononthediscussionoftheempulsetrial AT mgglezer empagliflozininpatientshospitalizedforacutedecompensatedheartfailureanexpertresolutiononthediscussionoftheempulsetrial AT ivzhirov empagliflozininpatientshospitalizedforacutedecompensatedheartfailureanexpertresolutiononthediscussionoftheempulsetrial AT mvilyin empagliflozininpatientshospitalizedforacutedecompensatedheartfailureanexpertresolutiononthediscussionoftheempulsetrial AT ayulebedeva empagliflozininpatientshospitalizedforacutedecompensatedheartfailureanexpertresolutiononthediscussionoftheempulsetrial AT svnedogoda empagliflozininpatientshospitalizedforacutedecompensatedheartfailureanexpertresolutiononthediscussionoftheempulsetrial AT vvsalukhov empagliflozininpatientshospitalizedforacutedecompensatedheartfailureanexpertresolutiononthediscussionoftheempulsetrial AT eitarlovskaya empagliflozininpatientshospitalizedforacutedecompensatedheartfailureanexpertresolutiononthediscussionoftheempulsetrial AT sntereshchenko empagliflozininpatientshospitalizedforacutedecompensatedheartfailureanexpertresolutiononthediscussionoftheempulsetrial AT ivfomin empagliflozininpatientshospitalizedforacutedecompensatedheartfailureanexpertresolutiononthediscussionoftheempulsetrial AT yushkhalimov empagliflozininpatientshospitalizedforacutedecompensatedheartfailureanexpertresolutiononthediscussionoftheempulsetrial AT dvcherkashin empagliflozininpatientshospitalizedforacutedecompensatedheartfailureanexpertresolutiononthediscussionoftheempulsetrial |